Interview mit:
Interview von:
Produziert von:
ESMO GI: Die wichtigsten Take Home Messages zu Lebermetastasen, Gallenwegs- und Pankreaskarzinomen
Prim. Univ.-Prof. Dr. Thomas Grünberger, Chirurgische Abteilung, Sozialmedizinisches Zentrum Süd – Kaiser-Franz-Josef-Spital mit Gottfried von Preyer’schem Kinderspital, fasst den State-of-the-art und die wichtigsten Neuigkeiten zur Therapie von Metastasen des Kolorektalkarzinoms, des Gallenwegskarzinoms und des Pankreaskarzinoms zusammen.
Im Interview spricht Prim. Univ.-Prof. Dr. Grünberger über die folgenden Sessions und Abstracts am ESMO World Congress on Gastrointestinal Cancer 2019:
- Expert Discussion: Synchronous Oligometastatic Colorectal Cancer
Wednesday, 3 July 12:30 – 14:45 - Multidisciplinary Tumor Board: A Challenging Patient with Colorectal Cancer. Session XX: Colorectal Cancer (Part II). Saturday, 6 July 2019 11:40 – 12:10
- Parikh A et al. Proof of Concept of the Abscopal Effect in MSS GI Cancers: A Phase 2 study of Ipilimumab and Nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma Abstract O-008
- Demols A et al. Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors. Abstract O-003
- Reni M et al. An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Abstract O-001
ESMO World Congress on Gastrointestinal Cancer 2019, Barcelona, Spain, 3-6 July 2019